• (1R,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass292.20 g·mol−1
3D model (JSmol)
  • C1C[C@H](C2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl)N
  • InChI=1S/C16H15Cl2N/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13/h1-5,7,9,11,16H,6,8,19H2/t11-,16+/m0/s1
 ☒NcheckY (what is this?)  (verify)

Dasotraline (INN;[1] former developmental code name SEP-225,289) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that was under development by Sunovion for the treatment of attention-deficit hyperactivity disorder (ADHD) and binge eating disorder (BED).[2][3][4][5] Structurally, dasotraline is a stereoisomer of desmethylsertraline (DMS), which is an active metabolite of the marketed selective serotonin reuptake inhibitor (SSRI) antidepressant sertraline (Zoloft).

Adverse Effects

In phase I clinical trials for ADHD, test subjects reported the following side effects:[6]


In 2017, the U.S. Food and Drug Administration accepted Sunovion's New Drug Application (NDA) for review for the treatment of ADHD;[7] however, the NDA was ultimately rejected citing the need for additional studies to determine efficacy and tolerability.[8][9][10] In July 2019, Sunovion’s NDA for the treatment of BED was accepted with an expected action date of May 2020.[11] In May 2020, Sunovion halted its drug development program for dasotraline, withdrawing both NDAs for ADHD and BED.[12]

See also


  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. WHO. 27 (4). 2013. Retrieved 4 November 2014.
  2. ^ Chen Z, Skolnick P (September 2007). "Triple uptake inhibitors: therapeutic potential in depression and beyond". Expert Opinion on Investigational Drugs. 16 (9): 1365–77. doi:10.1517/13543784.16.9.1365. PMID 17714023. S2CID 20271918.
  3. ^ DeLorenzo C, Lichenstein S, Schaefer K, Dunn J, Marshall R, Organisak L, et al. (July 2011). "SEP-225289 serotonin and dopamine transporter occupancy: a PET study". Journal of Nuclear Medicine. 52 (7): 1150–5. doi:10.2967/jnumed.110.084525. PMC 3856248. PMID 21680689.
  4. ^ Ziegler L, Küffer G, Euler E, Wilhelm K (August 1990). "[Arthrographic imaging of ganglions of the hand]" [Arthrographic imaging of ganglions of the hand]. RöFo (in German). 153 (2): 143–6. doi:10.1055/s-2008-1033352. PMID 2168068.
  5. ^ Guiard B, Chenu F, El Mansari M, Blier P (2009). "P.1.c.059 Electrophysiological properties of the triple reuptake inhibitor SEP 225289 on monoaminergic neurons". European Neuropsychopharmacology. 19: S285. doi:10.1016/S0924-977X(09)70419-5. S2CID 54263757.
  6. ^ Koblan KS, Hopkins SC, Sarma K, Jin F, Goldman R, Kollins SH, Loebel A (November 2015). "Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults". Neuropsychopharmacology. 40 (12): 2745–52. doi:10.1038/npp.2015.124. PMC 4864650. PMID 25948101.
  7. ^ "Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD" (Press release). Marlborough, Massachusetts: Sunovion. Business Wire. November 10, 2017. Retrieved 2018-05-01.
  8. ^ "FDA Issues a Complete Response Letter for New Drug Application for Dasotraline for the Treatment of Adhd". Sumitomo Dainippon Pharma Co., Ltd. August 31, 2018.
  9. ^ "Pipeline Report: Brand Drugs" (PDF). Welldyne. February 2018. pp. 1, 4. Retrieved 1 May 2018.
  10. ^ Clinical trial number NCT02276209 for "Dasotraline Adult ADHD Study" at ClinicalTrials.gov
  11. ^ "Sunovion Announces Acceptance by the US FDA of the New Drug Application for Dasotraline for the Treatment of Adults with Moderate-to-Severe Binge Eating Disorder". Sumitomo Dainippon Pharma Co., Ltd. July 30, 2019.
  12. ^ "Sunovion Discontinues Dasotraline Program". www.businesswire.com. 13 May 2020. Retrieved 27 June 2020.

Further reading

Liming Shao Patent
Asymmetry Patent